Bupivacaine Hydrochloride

+ 38 more variants

• Urinary Retention: Difficulty urinating after the procedure, common with spinal/epidural use as the nerves controlling the bladder are temporarily numbed.
• Pruritus (Itching): More common if the bupivacaine is mixed with opioid medications.
• Paresthesia: A 'pins and needles' sensation as the block wears off.
• Bradycardia: A slight slowing of the heart rate.
• Shivering: Often occurs during the recovery phase of regional anesthesia.

• Nerve Injury: Extremely rare, but localized nerve damage can occur from the needle or the pressure of the injection.
• Methemoglobinemia: A condition where the blood cannot carry oxygen effectively; though more common with other anesthetics, it has been reported with bupivacaine.
• Toxicity (LAST): Systemic absorption leading to CNS or cardiac symptoms.

> Warning: Stop the administration (if on a pump) and alert medical staff immediately if you experience any of these symptoms.

• Seizures: Sudden, uncontrolled electrical activity in the brain caused by high systemic levels of bupivacaine.
• Cardiac Arrest: Bupivacaine is notoriously cardiotoxic in high doses, making it difficult to restart the heart if it stops.
• Difficulty Breathing: This can occur if a spinal or epidural block 'travels' too high and affects the nerves controlling the diaphragm.
• Severe Allergic Reaction (Anaphylaxis): Symptoms include hives, swelling of the face or throat, and difficulty swallowing.
• Loss of Sensation that Does Not Return: Prolonged numbness or weakness well beyond the expected duration of the drug.

Bupivacaine is generally intended for short-term use. However, some long-term concerns exist:

• Chondrolysis: There have been reports of permanent damage to joint cartilage (chondrolysis) when bupivacaine is administered via a continuous intra-articular infusion pump (e.g., into the shoulder joint) after surgery. This is NOT an approved use of the drug.
• Persistent Neuropathy: In very rare cases, patients may experience long-term tingling or weakness in the area where a nerve block was performed.

0.75% Bupivacaine Concentration Warning: The FDA has issued a Black Box Warning for the 0.75% concentration of bupivacaine. It is strictly contraindicated for obstetrical anesthesia (epidural use during labor). There have been reports of cardiac arrest with difficult resuscitation or death during epidural anesthesia in obstetrical patients using this high concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. The 0.75% concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.

Report any unusual symptoms to your healthcare provider.

During bupivacaine administration, the following must be monitored continuously:

• Electrocardiogram (ECG): To detect early signs of cardiac rhythm changes.
• Blood Pressure: To manage hypotension, especially during epidural or spinal use.
• Oxygen Saturation (Pulse Oximetry): To ensure adequate oxygenation.
• Mental Status: Changes in consciousness or 'feeling funny' can be early signs of CNS toxicity.

Bupivacaine can temporarily impair motor function and coordination. Patients should not drive or operate heavy machinery until the full effects of the anesthesia have worn off and they have regained full sensation and muscle strength. This typically takes several hours after the last dose.

Alcohol should be avoided for at least 24 hours after receiving bupivacaine. Alcohol can enhance the central nervous system depressant effects of any residual anesthetic and may increase the risk of falls or injury while sensation is still impaired.

For single-dose blocks, the drug naturally wears off. For continuous infusions, the dose is typically tapered or stopped once oral pain medications are sufficient. There is no 'withdrawal' syndrome, but a rebound increase in pain (breakthrough pain) may occur if alternative analgesia is not provided.

> Important: Discuss all your medical conditions with your healthcare provider before starting Bupivacaine.

• CYP3A4 Inhibitors: Drugs like Ketoconazole, Ritonavir, or Clarithromycin inhibit the enzyme responsible for breaking down bupivacaine. This can lead to higher-than-expected levels of bupivacaine in the blood, especially during long-term infusions.
• Hyaluronidase: Sometimes added to local anesthetics to increase spread, but it may also increase the rate of systemic absorption, potentially shortening the block and increasing toxicity risk.

Since bupivacaine is administered via injection for acute procedures, food interactions are generally not a concern. However, patients should follow their surgeon's 'NPO' (nothing by mouth) instructions prior to any procedure involving anesthesia.

• St. John's Wort: May induce CYP3A4 enzymes, potentially leading to faster clearance of bupivacaine, though this is rarely clinically significant for a single dose.
• Garlic, Ginkgo, Ginseng: These supplements can increase bleeding risk. While they don't interact with bupivacaine directly, they can increase the risk of a hematoma (blood clot) at the site of a spinal or epidural injection.

Bupivacaine does not typically interfere with standard laboratory blood tests. However, the presence of epinephrine in some bupivacaine formulations may cause a transient increase in blood glucose levels.

For each major interaction, the management strategy involves:

• Mechanism: Usually additive pharmacodynamic effects (on the heart/nerves) or pharmacokinetic changes (CYP3A4 inhibition).
• Consequence: Increased risk of LAST or reduced duration of anesthesia.
• Management: Dose reduction of bupivacaine and continuous ECG monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Conditions requiring careful risk-benefit analysis:

• Coagulopathy: Patients on blood thinners (like warfarin) or those with low platelets are at high risk for spinal/epidural hematoma, which can cause permanent paralysis.
• Pre-existing Neurological Disease: Conditions like Multiple Sclerosis may be exacerbated by regional anesthesia, though data is inconclusive.
• Heart Block: Bupivacaine can slow electrical conduction in the heart, worsening existing arrhythmias.
• Liver Disease: Reduced metabolism increases the risk of systemic toxicity.

Patients allergic to one amide local anesthetic are likely to be allergic to others in the same class. However, they may be able to safely receive 'ester-type' local anesthetics (like procaine or tetracaine), provided the allergy is confirmed to be class-specific. Always inform your anesthesiologist of any previous 'caine' allergies.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Bupivacaine.

Bupivacaine is approved for use in children for various types of regional anesthesia. However, because children have different metabolic rates and higher body water content, weight-based dosing (mg/kg) is mandatory. The 0.75% concentration is not recommended for children. Safety and effectiveness in children under the age of 2 have not been fully established for all types of blocks.

Patients over age 65 are at a higher risk of bupivacaine-related complications.

• Pharmacokinetics: Reduced cardiac output and hepatic blood flow lead to slower clearance.
• Sensitivity: The elderly may experience more profound hypotension during spinal or epidural anesthesia.
• Dosing: Clinicians typically start at the lower end of the dosing range and titrate slowly.

In patients with kidney failure, the clearance of bupivacaine metabolites may be reduced. While a single dose is usually safe, continuous infusions require careful monitoring for signs of systemic toxicity, as the parent drug and its metabolites can accumulate over several days.

Patients with severe hepatic impairment (Child-Pugh Class C) have a significantly reduced ability to metabolize bupivacaine. This increases the half-life and the risk of Local Anesthetic Systemic Toxicity (LAST). Dose reductions of 25% to 50% may be necessary for these patients.

> Important: Special populations require individualized medical assessment.

Pharmacokinetics

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Systemic absorption from site) |

| Protein Binding | 95% (Alpha-1-acid glycoprotein) |

| Half-life | 2.7 hours (Adults), 8.1 hours (Neonates) |

| Tmax | 30 - 45 minutes (after infiltration) |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Renal (95% as metabolites, 5% unchanged) |

• Molecular Formula: C18H28N2O
• Molecular Weight: 288.43 g/mol
• Solubility: Soluble in water and ethanol.
• Structure: A white crystalline powder; chemically, it is 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide.

Bupivacaine is a member of the Amide Local Anesthetic class. It is structurally related to lidocaine and mepivacaine but is more lipid-soluble and potent. It is often compared to Ropivacaine, which is a pure S-enantiomer designed to have less cardiotoxicity than racemic bupivacaine.